Skip to main content
. 2000 Jun;74(12):5679–5690. doi: 10.1128/jvi.74.12.5679-5690.2000

TABLE 2.

Gag-specific CTL responses in the Durban cohorts studied

Best-recognized peptide Subjecta HLA class I type CTL (per one million PBMCs) Defined dominant epitope [HLA restriction]
p17c.4 RCC-001 A3/23 B49/5802 Cw6/- 1,000 RLRPGGKKK [A3]
RCC-002 A*3001/66 B42/81 Cw4/17 >1,000 RLRPGGKKHYMIKHLVW [NDb]
338-M A2/69 B7/42 Cw7/17 >1,000 RLRPGGKKHYMIKHLVW [ND]
KEH04-M A30/- B42/72 Cw2/17 354 RLRPGGKKHYMIKHLVW [ND]
p17c.7 RCC-006 A6801/- B62/71 Cw-/- 600 LVWASRELERFALNPGL [ND]
RCC-007 ND 1,000 LVWASRELERFALNPGL [ND]
p17c.11 338-M A2/69 B7/42 Cw7/17 >1,000 IIKQLQPALQTGTEEL [ND]
p17c.13 338-M A2/69 B7/42 Cw7/17 >1,000 SLYNTVATL [A2]
325-M A3/30 B*5802/72 Cw2/6 >1,000 ELRSLYNTVATLYCV [ND]
200-M ND 1,500 ELRSLYNTVATLYCV [ND]
KEH18-M A*6802/- B44/*5802 Cw4/6 320 ELRSLYNTVATLYCV [ND]
p24c.3 994-M A3/74 B57/62 Cw04/- 760 NAWVKVIEEKAFSPEVIPF [ND]
p24.5 1020-C5Y A2/*3002 B14/*5802 Cw6/8 640 TPQDLNTML [ND]
1023-C6W A24/30 B8/72 Cw2/7 540 TPQDLNTML [ND]
021-M A1/34 B72/81 Cw2/18 >1,000 SALSEGATPQDLNTMLNTVG [ND]
023-M A29/3002 B7/42 Cw7/17 >1,000 SALSEGATPQDLNTMLNTVG [ND]
252-M A29/*6802 B18/*5802 Cw5/6 >1,000 SALSEGATPQDLNTMLNTVG [ND]
270-M A23/*6802 B41/71 Cw3/17 >1,000 SALSEGATPQDLNTMLNTVG [ND]
272-M A30/34 B*5802/81 Cw6/18 >1,000 SALSEGATPQDLNTMLNTVG [ND]
298-M A1/*6801 B*5802/81 Cw6/18 >1,500 SALSEGATPQDLNTMLNTVG [ND]
982-M ND >1,000 TPQDLNTML [ND]
987-M A2/*3002 B*5801/81 Cw04/- >1,000 TPQDLNTML [ND]
991-M A1/*3002 B8/81 Cw7/18 980 TPQDLNTML [ND]
1023-M A2/24 B8/*5802 Cw6/7 >1,000 SALSEGATPQDLNTMLNTVG [ND]
1031-M ND >1,000 TPQDLNTML [ND]
KEH01-M A30/68 B14/42 Cw8/17 380 SALSEGATPQDLNTMLNTVG [ND]
KEH02-M A30/- B42/72 Cw2/17 900 SALSEGATPQDLNTMLNTVG [ND]
KEH19-M A*3002/66 B42/*5802 Cw6/17 920 TPQDLNTML [B42]
p24c.16 RC-005 ND 520 NPPIPVDIYKRWII [ND]
973-M A1/3 B8/- Cw7/- 1,860 DIYKRWII [B8]
p24c.17 1020-M A2/- B*5802/62 Cw4/6 900 GLNKIVRMY [ND]
p24c.20 RCC-007 ND 1,000 SILDIKQGPKEPFRDY [ND]
109-M A2/23 B72/- Cw2/- 420 SILDIKQGPKEPFRDY [ND]
188-M A2/*6801 B18/*5802 Cw5/6 720 SILDIKQGPKEPFRDY [ND]
260-M ND 173 SILDIKQGPKEPFRDY [ND]
p24c.22 RCC-004 A23/69 B-/- Cw3/18 >1,000 FRDYVDRFFKTLRAEQA [ND]
022-M A*3001/*3002 B42/45 Cw3/17 380 FRDYVDRFFKTLRAEQA [ND]
270-M A23/*6802 B41/71 Cw3/17 >1,000 FRDYVDRFFKTLRAEQA [ND]
971-M A26/68 B8/71 Cw3/7 1,080 FRDYVDRFFKTLRAEQA [ND]
1011-M A*6802/74 B71/- Cw3/4 840 FRDYVDRFFKTLRAEQA [ND]
p24c.24 RCC-004 A23/69 B-/- Cw3/18 >1,000 QATQDVKNWMTDTLLV [ND]
p24c.25 RC-007 ND 520 WMTDTLLVQNANPDCKTI [ND]
p24c.28 KEH14-M A3/33 B71/72 Cw-/- 340 EEMMTACQGVGGPSHKARVL [ND]
a

Subjects coded by a number followed by “M” represent adults in the cohort. All subjects were of the African racial group. 

b

ND, not determined. 

HHS Vulnerability Disclosure